Navigation Links
DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
Date:8/5/2013

been selected.
  • Relday (Risperidone Program). In January 2013, Zogenix (our licensee) announced positive single-dose pharmacokinetic (PK) results from a Phase 1 clinical trial of Relday. According to Zogenix, adverse events in the Phase 1 trial in patients diagnosed with schizophrenia were generally mild to moderate and consistent with other risperidone products. The Phase 1 clinical trial for Relday was conducted as a single-center, open-label, safety and PK trial of 30 patients with chronic, stable schizophrenia or schizoaffective disorder. Per Zogenix, based on the favorable safety and PK profile demonstrated with the 25 mg and 50 mg once-monthly doses tested in the Phase 1 trial, Zogenix extended the study to include a 100 mg dose of the same formulation. In May 2013, Zogenix announced positive results with the 100 mg arm, demonstrating dose proportionality across the full dose range that would be anticipated to be used in clinical practice. According to Zogenix, the positive results from this study extension positions Zogenix to begin a multi-dose clinical trial, which would provide the required steady-state pharmacokinetic and safety data prior to initiating Phase 3 development studies, subject to Zogenix's ability to secure a development and commercialization partner prior to initiation of the multi-dose trial.
    Relday is a proprietary, long-acting, once-monthly subcutaneous injectable formulation of risperidone using DURECT's SABER controlled-release formulation technology. An existing long-acting injectable risperidone product, which achieved $1.4 billion in global net sales in 2012, requires twice-monthly, intramuscular injections and drug reconstitution prior to use.
  • Feasibility Projects and Other Activities. During the second quarter of 2013, we continued work on several feasibility projects as a means of demonstrating that our technologies can achieve the drug delivery objectives set forth by
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    2. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
    3. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
    4. DURECT to Participate in Upcoming Healthcare Conferences
    5. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
    6. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
    7. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
    8. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
    9. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
    10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
    11. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
    (Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
    (Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
    Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
    ... U.S. Food and Drug Administration has scheduled its fourth ... those unfamiliar with the process for Feb. 28 – ... Keck Graduate Institute. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... Organization of Rare Disorders and the Genetic Alliance, will ...
    ... /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical ... today announced that Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), ... a "Top Ten Branded Company Trusted by Consumers" ...
    Cached Medicine Technology:Fourth FDA Orphan Drug Designation Workshop Scheduled for Feb. 28 - March 1, 2011 2China Sky One Medical Receives Medical Industry Awards 2China Sky One Medical Receives Medical Industry Awards 3
    (Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
    (Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
    (Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
    (Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
    (Date:1/22/2015)... released a new blog post explaining the importance of keeping a ... of an auto insurance policy . , Clients who driver ... their vehicle insurance policies. The safety a vehicle offers from its ... of this, drivers should always carry a first aid kit in ...
    Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
    ... Discussions Also to Feature Top Experts on the Battle Against H1N1 ... reform headed to the floor of the House and Senate, the ... discussions designed to shed light on what the looming changes will ... the Top of the Hill Banquet and Conference Center, at the ...
    ... Company allegedly failed to correct violations , ... of Justice, on behalf of the U.S. Food and ... against Rel,s Foods Inc. (Rel,s), of Oakland, Calif., seeking ... adulterated food products. , (Logo: ...
    ... Rawat Foundation,s grant to St. John of Jerusalem Eye Hospital will ... 8 A $25,000 grant by The Prem Rawat Foundation (TPRF) ... eye care for 30,000 children in an area of the world ... 50% of the people in the Palestinian Territories, one of the ...
    ... infection with high-risk types of human papillomavirus (HPV), a ... of cervical cancer. Current guidelines prioritize HPV vaccination of ... in previous studies, but the value of vaccinating boys ... new study, Harvard School of Public Health (HSPH) researchers ...
    ... Palliative Care Psychiatry Program only one of its kind ... The Palliative Care Psychiatry Program at San ... named the winner of the 2009 Gold Achievement Award by ... Irwin, MD, PhD is Director of the Palliative Care Psychiatry ...
    ... Reportlinker.com announces that a new market ... , Reportlinker Adds The Market ... Pharmaceutical, Diagnostic and Device Product Markets ... , At their most basic level, wellness ...
    Cached Medicine News:Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 2Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 3Health News:FDA Takes Enforcement Action Against Ready-to-Eat Sandwich Manufacturer 2Health News:TPRF Gives US$25,000 to Help Provide Eye Care for Children in Palestinian Territories 2Health News:Vaccinating boys against human papillomavirus not cost-effective 2Health News:Vaccinating boys against human papillomavirus not cost-effective 3Health News:San Diego Hospice and The Institute for Palliative Medicine Program Wins National American Psychiatric Association Gold Achievement Award 2Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 2Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 3Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 4Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 5Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 6Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 7Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 8Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 9Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 10Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 11Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 12Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 13
    Unipolar Atrial "J" Lead...
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
    Medicine Products: